Terumo and GenCure sign agreement for cell and gene therapies

SourcePharmaceutical Technology
Date Published06/29/2022
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name GenCure
Parent companyBioBridge Global
If manufacturing, is the company a contract manufacturer?Yes
Reshoring category:Reshoring
Year reshoring announced:2022
City reshored to:San Antonio
State(s) reshored to:TX
If relevant, work nearshored to:-
Product(s) reshoredcell and gene therapy solutions
What domestic positive factors made reshoring more attractive?Automation/technology, Customization/Flexibility, Eco-system synergies, Manufacturing/engineering joint innovation (R&D)
Find Reshoring Articles